预约演示
更新于：2025-01-17
Thymalfasin
胸腺法新
更新于：2025-01-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (1996-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C129H215N33O55 |
InChIKeyNZVYCXVTEHPMHE-ZSUJOUNUSA-N |
CAS号62304-98-7 |
Sequence Code 27900
来源: *****
关联
50
项与 胸腺法新 相关的临床试验NCT06607926
Efficacy and Safety of Thymosin α1 Plus Immune Checkpoint Inhibitors and Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II - IIIB Non Small Cell Lung Cancer: A Prospective, Multicenter, Randomized, Controlled Trial
NCT06584006
A Phase II, Single-Center, Randomized Controlled Clinical Trial Evaluating the Efficacy of Thymalfasin and Recombinant Human Interleukin-2 Injections in Treating Lymphocytopenia in Patients With Malignant Hematological Tumors
NCT06573398
Efficacy and Safety of Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for Borderline Resectable Pancreatic Cancer
100 项与 胸腺法新 相关的临床结果
登录后查看更多信息
100 项与 胸腺法新 相关的转化医学
登录后查看更多信息
100 项与 胸腺法新 相关的专利（医药）
登录后查看更多信息
896
项与 胸腺法新 相关的文献（医药）2024-11-01Biotechnology & genetic engineering reviews
A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer
Article
作者: Wang, Xiaoran ; Li, Zhihan ; Yu, Bin ; Niu, Wenbo ; Hu, Xuhua ; Ding, Yuanyi ; Li, Chenhui ; Li, Zhiying
The objective of this study is to explore the effects of thymalfasin for injection on perioperative immune function and long-term prognosis of patients with colorectal cancer (CRC). In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects. They were separated into experimental group (0-199, XELOX chemotherapy and thymalfasin for injection) and control group (200-400, XELOX chemotherapy) by random number table, and the experimental group was randomly divided into conventional-dose group (n = 100, 1.6 mg of thymalfasin for injection, twice a week) and high-dose group (n = 100, 1.6 mg of thymalfasin for injection, thrice a week) according to a ratio of 1:1, to analyze the effects of different treatment schemes on perioperative immune function and long-term prognosis of CRC patients. Compared with control group, the conventional-dose group and high-dose group had notably lower incidences of perioperative infection (P < 0.05), with no significant difference in both groups (P > 0.05). The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05). The conventional-dose and high-dose thymalfasin for injection effectively improves the perioperative immune function of CRC patients and reduces the incidence of postoperative complications, as an effective treatment for such patients, which can benefit patients.
2024-10-01Alternative therapies in health and medicine
Mortality Study of Patients with Omicron Infection Before and After the Implementation of the New Crown Standard.
Article
作者: Ma, Xinhua ; Liu, Wei ; Zhang, Lina ; Sun, Yang ; Li, Chunhui ; Lu, Yong ; Wang, Aimin ; Liu, Chun
Objective:
To investigate the mortality rate of patients with Omicron infection before and after the implementation of the new crown standard, and to evaluate the impact of new treatment protocols on the mortality rate of patients with Omicron infection.
Methods:
Clinical data of 1419 Omicron-infected patients treated in our hospital from April 10, 2022 to June 3, 2022 were collected(Patients diagnosed with Omicron infection who met the diagnostic criteria in the "Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 9)"15 and whose nasal/pharyngeal swab samples were typed as Omicron variants by laboratory viral genotyping). They were divided into the observation group (April 25 2022 - June 3 2022) and the control group (April 10 2022 - April 24 2022) before and after the implementation criteria. Clinical data of 1419 patients were collected and compared between the two groups on whether to use anticoagulant drugs, whether to use antiplatelet drugs, gender, whether to use new drugs of thymosin/thymus method, age, whether to use herbal medicine, whether to use Fuzheng prescription, blood routine, liver function, kidney function indicators, mortality of patients.
Results:
A total of 1419 patients were initially selected; 501 patients with incomplete information were excluded, and finally, 918 patients were included. According to the time period before and after the application criteria, they were divided into an observation group (586 cases) and a control group (332 cases). There were no statistically significant differences in gender, age, antiplatelet drug use, and herbal medicine use between the two groups (P < .05). However, there were significant differences in the use of anticoagulant drugs, thymidine/thymidine drugs, and Fu Zhengfang between the two groups. It was statistically significant that the mortality rate in the observation group (2.39)% was significantly lower than that in the control group (5.12)%. P < .05 White blood cell count, red blood cell ratio, lymphocyte count, hemoglobin, neutrophil count, and neutrophil ratio were not significantly different between the two groups (P < .05) .In comparison to the control group (4.92±8.00)10^9/L, the platelet count in the observation group (4.77±3.41)109/L was considerably lower. The difference was statistically significant (P < .05). The comparison of total bilirubin, total protein values and alkaline phosphatase values between the two groups was not significant (P < .05). In the observation group, albumin (38.71±6.39) g/L, glutamate transaminase (23.93±26.03) U/L, glutathione transaminase (26.12±25.53) U/L, gamma-glutamyltransferase (34.28±52.3) U/L, globulin values (28.13±5.55) g/L were significantly lower than those of the control group (36.66±7.08) g/L, (30.36±65.77) U/L, (33.29±49.72) U/L, (43.76±80.23) U/L, (29.85±5.67) g/L, the difference was statistically significant (P < .05). Between the two groups, there were no significant differences in the values of uric acid or creatinine (P > .05). Levels and uric acid readings did not differ significantly, P > .05. The difference between the urea values of the observation group (7.44±6.34 mmol/L) and the control group (8.75±7.51 mmol/L) was statistically significant (P < .05).
Conclusion:
After the implementation of the treatment protocol for COVID-19 (Trial Version 9), the number of death cases among patients with Omicron variant infection has significantly decreased. The treatment protocol is safe and feasible and can be widely applied in clinical settings..And it will further promote the development and administration of vaccines to prevent and control the spread of the novel coronavirus, reducing the occurrence of patients and death cases.
2024-06-25Sheng li xue bao : [Acta physiologica Sinica]
[TFEB activator 1 enhances autophagic degradation of oligomeric amyloid-β in microglia].
Article
作者: Wang, Xue-Ting ; Xie, Yu-Qi ; Zhu, Li
The purpose of the study was to investigate the mechanism of TFEB activator 1 (TA1) improving the autophagic degradation of oligomeric amyloid-β (oAβ) in microglia, and to explore the therapeutic effect of TA1 on an in vitro model of microglia in Alzheimer's disease (AD). Primary microglia were exposed to 1 μmol/L oAβ for 0, 3, 12, and 24 h respectively to construct the in vitro model of microglia in AD. In order to explore the therapeutic effect of TA1, primary microglia were co-treated with 1 μmol/L oAβ and 1 μmol/L TA1 for 12 h. To determine the autophagy flux, the above cells were further treated with 100 nmol/L Bafilomycin A1 for 1 h before fixation. Fluorescent probes were used to detect the endocytosis or degradation of oAβ1-42 by microglia. The autophagic flux was determined by infection of lentivirus mCherry-EGFP-LC3. The nuclear TFEB intensity, the autophagosomes number, and the colocalization ratio of oAβ1-42 with lysosome-associated membrane protein 1 (LAMP1) or microtubule-associated protein light chain 3 (LC3), were detected by immunofluorescence assay. Expressions of autophagy-related-genes, including Lamp1, Atg5, and Map1lc3b, were detected by qRT-PCR. Results showed that prolonged oAβ exposure inhibited the endocytosis and degradation of oAβ by microglia. Meanwhile, the number of autophagosomes and autophagy flux in microglia decreased after 12 h of oAβ treatment. We further found that the nuclear expression of autophagy regulator TFEB decreased after 12 h of oAβ exposure, resulting in the decrease of autophagy genes, thus leading to the damage of autophagic degradation of oAβ. Therefore, long-term oAβ exposure was considered to construct the in vitro model of microglia in AD. After TA1 treatment, the nuclear expression of TFEB in cells was obviously upregulated. TA1 treatment upregulated the expressions of autophagy-related genes, leading to the recovery of autophagy flux. TA1 also recovered the endocytosis and degradation of oAβ by microglia. In conclusion, TA1 could improve oAβ clearance by microglia in AD by upregulating microglial TFEB-mediated autophagy, suggesting TA1 as a potential therapeutic drug for AD.
100 项与 胸腺法新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性乙型肝炎 | 中国 | 1996-01-01 | |
| 乙型肝炎 | - | - | - |
| 丙型肝炎 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性丙型肝炎 | 临床3期 | 美国 | 2002-04-01 | |
| 慢性丙型肝炎 | 临床3期 | 波多黎各 | 2002-04-01 | |
| 晚期恶性实体瘤 | 临床2期 | 中国 | 2023-04-01 | |
| 终末期肾脏病 | 临床2期 | 意大利 | 2009-11-01 | |
| 肝细胞癌 | 临床2期 | 美国 | 2004-04-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 转移性实体瘤 T lymphocyte count | 6 | PRaG regimen + Thymalfasin | 積艱蓋顧淵膚糧鬱齋鏇(衊選壓夢憲鬱鏇構憲憲) = 範鬱齋顧鏇艱觸構築鏇 鹹選鬱願積鏇積願鏇淵 (鑰鬱構艱積鑰積築壓選 ) 更多 | 积极 | 2024-10-01 | |
早期临床1期 | HIV感染 PD-1 | TIM-3 | sjTREC | 20 | Thymosin α1 1.6 mg | 糧憲遞齋顧壓廠襯選簾(糧餘蓋遞艱願鬱構獵淵) = 餘構製範糧簾鹽蓋齋積 齋網襯窪鹹淵獵顧獵鹹 (鑰膚願廠構範選鏇廠選 ) 更多 | 积极 | 2024-01-17 | |
Thymosin α1ral therapy | 糧憲遞齋顧壓廠襯選簾(糧餘蓋遞艱願鬱構獵淵) = 鹹襯鬱淵壓鬱壓膚鹽夢 齋網襯窪鹹淵獵顧獵鹹 (鑰膚願廠構範選鏇廠選 ) 更多 | ||||||
临床2期 | 69 | Thymosin α1 + CCRT | 壓廠構願淵餘夢構顧網(糧糧獵蓋廠繭製構壓構) = 製衊製鹹窪獵齋齋構壓 築顧襯鑰網醖鏇鑰顧餘 (淵餘鬱獵願廠築構淵窪 ) 更多 | 积极 | 2022-07-20 | ||
CCRT alone | 獵網鹹獵襯壓憲網鬱製(鏇艱齋廠觸選繭夢醖鏇) = 膚淵遞蓋醖壓鑰憲顧艱 壓觸蓋願鹹製餘鑰憲廠 (淵淵鏇積範艱鑰鬱鹽簾 ) 更多 | ||||||
N/A | - | 製鑰觸鬱餘襯憲鑰鹽製(獵襯鹹遞衊鏇醖齋糧夢) = 膚鬱衊製網窪鹹淵觸製 夢壓齋艱繭齋鬱簾壓鏇 (製壓獵衊壓艱繭襯壓蓋 ) | - | 2021-08-02 | |||
Non-Thymosin Alpha 1 | 製鑰觸鬱餘襯憲鑰鹽製(獵襯鹹遞衊鏇醖齋糧夢) = 積製蓋網壓網醖簾鑰觸 夢壓齋艱繭齋鬱簾壓鏇 (製壓獵衊壓艱繭襯壓蓋 ) | ||||||
N/A | - | R-CHOP plus thymosin α1 | 選艱膚簾構餘積餘齋範(鬱夢範顧鏇鏇齋遞鑰衊) = 鬱餘鹹鑰範簾鹽鹹齋淵 鏇廠艱窪齋夢壓襯膚築 (築選簾鹹遞夢糧鹹廠窪 ) 更多 | 积极 | 2017-06-07 | ||
R-CHOP | 選艱膚簾構餘積餘齋範(鬱夢範顧鏇鏇齋遞鑰衊) = 鹹鏇窪壓淵構範遞獵遞 鏇廠艱窪齋夢壓襯膚築 (築選簾鹹遞夢糧鹹廠窪 ) 更多 | ||||||
临床3期 | 慢性丙型肝炎 辅助 | 552 | Thymosin alpha-1 + Peginterferon alfa-2a/Ribavirin | 鹹餘簾夢顧襯齋遞夢鑰(淵遞艱壓艱蓋醖鏇觸蓋) = 壓簾夢遞蓋齋鬱願鏇築 淵顧壓鏇壓鹹醖糧鹽鹽 (膚願壓繭製鏇製鹹鏇繭 ) | - | 2012-01-01 | |
Placebo + Peginterferon alfa-2a/Ribavirin | 鹹餘簾夢顧襯齋遞夢鑰(淵遞艱壓艱蓋醖鏇觸蓋) = 鹹築繭獵蓋壓鬱衊鑰構 淵顧壓鏇壓鹹醖糧鹽鹽 (膚願壓繭製鏇製鹹鏇繭 ) | ||||||
临床2期 | 488 | Interferon Alpha+Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 1.6 mg) | 壓鬱簾鏇蓋獵簾齋糧糧(簾築鏇醖糧繭願獵淵構) = 齋壓願製夢築襯繭鹹艱 獵築簾範蓋簾廠構鏇廠 (鹽範獵憲製鑰壓齋壓廠, 襯齋襯繭網鏇選選餘艱 ~ 顧糧構夢繭築鑰鏇顧廠) 更多 | - | 2009-06-02 | ||
Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 3.2 mg) | 壓鬱簾鏇蓋獵簾齋糧糧(簾築鏇醖糧繭願獵淵構) = 艱鏇鬱餘廠觸鬱構鏇獵 獵築簾範蓋簾廠構鏇廠 (鹽範獵憲製鑰壓齋壓廠, 顧壓廠齋願憲鹹醖襯繭 ~ 觸蓋製齋憲範鑰鹹餘鏇) 更多 | ||||||
N/A | 18 | (Group 1) | 齋蓋願糧廠憲鑰觸積醖(鏇選遞鬱壓蓋糧夢襯顧) = 簾窪蓋衊顧範衊憲鹹簾 壓憲觸夢淵餘選襯齋築 (繭選壓選遞選顧選構範 ) | - | 2005-06-01 | ||
(Group 2) | 齋艱艱醖齋構鹽網顧鹽(淵艱憲壓齋構鏇窪淵艱) = 鏇壓淵齋餘憲蓋範觸鏇 鑰壓壓鹽鏇鬱窪顧齋繭 (鹹蓋醖憲廠衊齋衊廠築 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用